Phase 3 Study: Sonrotoclax, BCL2 Inhibitor, with Anti-CD20 Therapies in R/R CLL/SLL.

This trial compares sonrotoclax combined with anti-CD20 antibodies to standard venetoclax plus rituximab in adults with relapsed/refractory CLL/SLL receiving second-line or later therapy. Conducted at multiple international sites and sponsored by BeiGene, the study evaluates safety and efficacy across four treatment arms, including an MRD-guided approach.